Skip to content

US · MGNX · BIOTECHNOLOGY

MacroGenics, Inc. (MGNX) intrinsic value and stock valuation

$1.96as of 2026-11-21 · Mkt cap 247.9M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

MacroGenics, Inc. DCF and intrinsic value

InvestorsCraft values MGNX with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from MGNX’s statements →

MacroGenics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Rockville, MD 20850 macrogenics.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$149.5M+8.9% 5y CAGRd
20112025
Net income
-$-74.62M
20112025
Free cash flow
-$-82.95M
20112025
Total equity
$55.6M-28.4% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$149.5M$148.3M$57.2M$150M$75.6M
Operating income-$-72.84M-$-110.58M-$-168.24M-$-121.42M-$-202.79M
Net income-$-74.62M-$-66.97M-$-9.06M-$-119.76M-$-202.12M
EPSd-$-1.18M-$-1.07M-$-146.29K-$-1.95M-$-3.37M
Operating cash flow-$-81.04M-$-68.37M-$-78.2M-$-86.96M-$-143.83M
Capital expenditure-$-1.91M-$-3.71M-$-1.76M-$-3.62M-$-6.2M
Free cash flow-$-82.95M-$-72.08M-$-79.97M-$-90.58M-$-150.03M
Total assets$256.9M$261.7M$298.4M$289.5M$335.3M
Total debt$106.8M$37.5M$34M$34.8M$25.5M
Net debt$49.6M-$-145.38M-$-66.98M-$-74.05M-$-98M
Total equity$55.6M$116.1M$152.6M$142M$239.6M
Cash and short-term investments$189.9M$201.7M$229.8M$154.4M$243.6M
Income statement
20252024202320222021
Revenue$149.5M$148.3M$57.2M$150M$75.6M
Cost of revenue$43.2M$12.3M$8.22M$7.38M$2.65M
Gross profit$106.3M$136M$49M$142.6M$73M
Research and development expenses$140M$177.2M$166.6M$207M$214.6M
Selling, general and administrative expenses$39.2M$71.1M$52.2M$59M$63M
Other expenses$0.00-$-1.62M-$-1.56M-$-1.92M-$-1.8M
Operating expenses$179.2M$246.6M$217.2M$264.1M$275.8M
Cost and expenses$222.3M$258.9M$225.4M$271.4M$278.4M
Interest income$3.4M$9.42M$9.69M$1.7M$680K
Interest expense$8.51M$1.11M$1.43M$0.00$0.00
Depreciation and amortization$7.17M$7.54M$9.64M$11.9M$11.3M
Ebitda-$-59.61M-$-57.37M$2.02M-$-107.89M-$-190.86M
Operating income-$-72.84M-$-110.58M-$-168.24M-$-121.42M-$-202.79M
Total other income/expenses, net-$-2.45M$44.6M$159.2M$1.66M$680K
Income before tax-$-75.29M-$-66.02M-$-9.06M-$-119.76M-$-202.12M
Income tax expense-$-670K$940K$0.00$0.00$0.00
Net income-$-74.62M-$-66.97M-$-9.06M-$-119.76M-$-202.12M
Weighted average shares outstanding$63.2M$62.6M$61.9M$61.4M$59.9M
Weighted average diluted shares outstanding$63.2M$62.6M$61.9M$61.4M$59.9M
Balance sheet
20252024202320222021
Cash and short-term investments$189.9M$201.7M$229.8M$154.4M$243.6M
Net receivables$13.4M$4.31M$10.4M$56.2M$10.4M
Inventory$7.91M$0.00$1.22M$1.45M$4.39M
Total current assets$219.9M$217.5M$251.3M$222.2M$279.6M
Property, plant and equipment, net$35.5M$42.6M$45.7M$56.9M$54.3M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$36.9M$53.1M$47.1M$67.3M$55.7M
Total assets$256.9M$261.7M$298.4M$289.5M$335.3M
Accounts payable$4.79M$5.01M$6.44M$4.9M$15.5M
Short-term debt$5.18M$4.86M$3.77M$4.73M$4.68M
Deferred revenue$10.9M$16.3M$21.7M$9.99M$0.00
Total current liabilities$43.1M$55.5M$56.1M$48.6M$74.6M
Long-term debt$101.6M$32.6M$30.2M$30.1M$20.8M
Deferred revenue, non-current$55.5M$55.5M$59.2M$59.5M$0.00
Total non-current liabilities$158.1M$99M$89.7M$98.9M$21.1M
Capital lease obligations$31.6M$37.5M$34M$30.1M$25.5M
Total liabilities$201.3M$145.6M$145.8M$147.5M$95.6M
Common stock$630K$630K$620K$620K$610K
Retained earnings-$-1.24B-$-1.17B-$-1.1B-$-1.09B-$-973.94M
Accumulated other comprehensive income (loss)$30K$0.00-$-10K-$-10K-$-60K
Total equity$55.6M$116.1M$152.6M$142M$239.6M
Total investments$132.7M$18.8M$128.9M$45.5M$120.2M
Total debt$106.8M$37.5M$34M$34.8M$25.5M
Net debt$49.6M-$-145.38M-$-66.98M-$-74.05M-$-98M
Cash flow statement
20252024202320222021
Net income-$-74.62M-$-66.97M-$-9.06M-$-119.76M-$-202.12M
Depreciation and amortization$5.52M$7.54M$9.64M$11.9M$11.3M
Stock-based compensation$14.3M$29.4M$18.4M$20.4M$23.1M
Change in working capital-$-28.33M$1.39M$53.3M-$-6.13M$17.6M
Accounts receivable-$-9.06M$6.06M$45.9M-$-45.84M$12.7M
Inventory-$-7.91M-$-2.19M$230K$60K-$-6.42M
Accounts payable-$-280K-$-1.53M$1.28M-$-10.86M$7.12M
Net cash provided by operating activities-$-81.04M-$-68.37M-$-78.2M-$-86.96M-$-143.83M
Investments in property, plant and equipment-$-1.91M-$-3.71M-$-1.76M-$-3.62M-$-6.2M
Acquisitions, net$10K$0.00$60K$0.00$0.00
Net cash used for investing activities-$-114.1M$149.3M-$-80.08M$70.7M-$-36.61M
Common stock issued$130K$3.44M$1.17M$1.08M$117.8M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$69.5M$960K$150.4M$1.66M$122.8M
Net change in cash-$-125.62M$81.9M-$-7.93M-$-14.59M-$-57.66M
Cash at end of period$57.2M$182.8M$101M$108.9M$123.5M
Operating cash flow-$-81.04M-$-68.37M-$-78.2M-$-86.96M-$-143.83M
Capital expenditure-$-1.91M-$-3.71M-$-1.76M-$-3.62M-$-6.2M
Free cash flow-$-82.95M-$-72.08M-$-79.97M-$-90.58M-$-150.03M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About MacroGenics, Inc.

        MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company’s product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.

        CEO
        Eric Risser
        Employees
        293
        Beta
        1.18

        Explore

        Frequently asked questions

        What is the intrinsic value of MacroGenics, Inc. (MGNX)?

        MacroGenics, Inc. (MGNX) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is MGNX undervalued?

        MGNX trades at a price of $1.96 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.